Clinical trials: sponsored by Arrowhead Pharmaceuticals
Asthma, Chronic Obstructive Pulmonary Disease
Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of ARO-MUC5AC in normal healthy volunteers (NHVs), patients with moderate-to-severe asthma and patients with moderate-to-severe chronic…
- Trial name
- NCT05292950
- Testing
- ARO-MUC5AC
- Where
- 13 sites in Australia, New Zealand and 5 more
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Idiopathic Pulmonary Fibrosis
Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARO-MMP7 in normal healthy volunteers (NHVs) and in participants with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT05537025
- Testing
- ARO-MMP7 Inhalation Solution
- Where
- 19 sites in Denmark, Italy and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Healthy
A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers
Single doses of ARC-520 will be evaluated at varying infusion rates and by slow bolus push.
- Trial name
- NCT02535416
- Testing
- ARC-520, cetirizine, diphenhydramine
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Alpha-1 Antitrypsin Deficiency
A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)
The purpose of the study is to determine the safety and tolerability of escalating doses of ARC-AAT and to evaluate the pharmacokinetics of ARC-AAT and the effect of ARC-AAT on circulating levels of alpha-1 antitrypsin (AAT).
- Trial name
- NCT02363946
- Testing
- ARC-AAT Injection, Diphenhydramine
- Where
- 4 sites in Australia, Germany and 2 more
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Hepatitis B
A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)
Normal healthy volunteer (NHV) participants will enroll sequentially into a total of 6 escalating dose levels (6 subjects per dose level), randomized to receive a single dose of ARC-521 Injection or placebo.
- Trial name
- NCT02797522
- Testing
- ARC-521 Injection, antihistamine, acetaminophen
- Where
- New Zealand
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Cystic Fibrosis, Pulmonary
Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single doses of ARO-ENaC in healthy adult volunteers; and to evaluate the safety, tolerability, PK and efficacy of multiple doses of…
- Trial name
- NCT04375514
- Testing
- ARO-ENaC
- Where
- 7 sites in Australia, New Zealand
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Hepatitis B
Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of ARO-HBV in healthy adult volunteers and participants with hepatitis B virus (HBV).
- Trial name
- NCT03365947
- Testing
- ARO-HBV, Sterile Normal Saline (0.9% NaCl), JNJ-56136379
- Where
- 7 sites in Australia, Hong Kong and 1 more
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Non-alcoholic Steatohepatitis
Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of single and multiple doses of ARO-HSD in healthy adult volunteers and in patients with NASH or suspected NASH.
- Trial name
- NCT04202354
- Testing
- ARO-HSD Injection, sterile normal saline (0.9% NaCl)
- Where
- New Zealand
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals